Parenteral Controlled and Prolonged Drug Delivery Systems: Therapeutic Needs and Formulation Strategies

Vhora, Imran; Bardoliwala, Denish; Ranamalla, Saketh Reddy; Javia, Ankit

doi:10.1007/978-981-13-3642-3_7

Cited by 6 publications

(2 citation statements)

References 193 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Q-Sphera™ technology is a novel platform to individually print narrow size distribution particles of approximate 30 μm to generate predictable pharmacokinetic profile. This micro-piezo technology was developed by the MidaTech 115 . Midatech's Q-Sphera technology focuses on long acting injectables using proprietary piezo printing technology that encapsulates PPDs into polymeric microparticles with precision properties.…”

Section: Formulation Technology With Combinational Strategiesmentioning

confidence: 99%

Oral delivery of protein and peptide drugs: from non-specific formulation approaches to intestinal cell targeting strategies

Chen¹,

Kang²,

Li³

et al. 2022

Theranostics

View full text Add to dashboard Cite

The past few years has witnessed a booming market of protein and peptide drugs, owing to their superior efficiency and biocompatibility. Parenteral route is the most commonly employed method for protein and peptide drugs administration. However, short plasma half-life protein and peptide drugs requires repetitive injections and results in poor patient compliance. Oral delivery is a promising alternative but hindered by harsh gastrointestinal environment and defensive intestinal epithelial barriers. Therefore, designing suitable oral delivery systems for peptide and protein drugs has been a persistent challenge. This review summarizes the main challenges for oral protein and peptide drugs delivery and highlights the advanced formulation strategies to improve their oral bioavailability. More importantly, major intestinal cell types and available targeting receptors are introduced along with the potential strategies to target these cell types. We also described the multifunctional biomaterials which can be used to prepare oral carrier systems as well as to modulate the mucosal immune response. Understanding the emerging delivery strategies and challenges for protein and peptide drugs will surely inspire the production of promising oral delivery systems that serves therapeutic needs in clinical settings.

show abstract

Section: Formulation Technology With Combinational Strategiesmentioning

confidence: 99%

Oral delivery of protein and peptide drugs: from non-specific formulation approaches to intestinal cell targeting strategies

Chen¹,

Kang²,

Li³

et al. 2022

Theranostics

View full text Add to dashboard Cite

show abstract

“…An ideal depot formulation delivers the drug at a tunable, predetermined rate within the therapeutic range for a specified period, ideally for as long as possible for the treatment of chronic diseases [7]. Release can take place directly at the site of action for a local treatment or at a systemic level, thus reducing the adverse side effects of the drug to a minimum [8]. Furthermore, the ideal delivery system undergoes full biodegradation at a rate consistent with the desired release rate of the API, and the matrix biocompatibility does not induce adverse reactions at the site of injection [9].…”

Section: The Ideal Depot Delivery Systemmentioning

confidence: 99%

Injectable Lipid-Based Depot Formulations: Where Do We Stand?

Rahnfeld

Luciani

2020

Pharmaceutics

View full text Add to dashboard Cite

The remarkable number of new molecular entities approved per year as parenteral drugs, such as biologics and complex active pharmaceutical ingredients, calls for innovative and tunable drug delivery systems. Besides making these classes of drugs available in the body, injectable depot formulations offer the unique advantage in the parenteral world of reducing the number of required injections, thus increasing effectiveness as well as patient compliance. To date, a plethora of excipients has been proposed to formulate depot systems, and among those, lipids stand out due to their unique biocompatibility properties and safety profile. Looking at the several long-acting drug delivery systems based on lipids designed so far, a legitimate question may arise: How far away are we from an ideal depot formulation? Here, we review sustained release lipid-based platforms developed in the last 5 years, namely oil-based solutions, liposomal systems, in situ forming systems, solid particles, and implants, and we critically discuss the requirements for an ideal depot formulation with respect to the used excipients, biocompatibility, and the challenges presented by the manufacturing process. Finally, we delve into lights and shadows originating from the current setups of in vitro release assays developed with the aim of assessing the translational potential of depot injectables.

show abstract

Long-acting parenteral formulations of hydrophilic drugs, proteins, and peptide therapeutics: mechanisms, challenges, and therapeutic benefits with a focus on technologies

Nakmode,

Singh,

Abdella

et al. 2024

Drug Deliv. and Transl. Res.

View full text Add to dashboard Cite

Despite being the most widely prescribed formulation, oral formulations possess several limitations such as low adherence, low bioavailability, high toxicity (in the case of anticancer drugs), and multiple-time administration requirements. All these limitations can be overcome by long-acting injectables. Improved adherence, patient compliance, and reduced relapse have been observed with long-acting formulation which has increased the demand for long-acting injectables. Drugs or peptide molecules with oral bioavailability issues can be easily delivered by long-acting systems. This review comprehensively addresses the various technologies used to develop long-acting injections with a particular focus on hydrophilic drugs and large molecules as well as the factors affecting the choice of formulation strategy. This is the first review that discusses the possible technologies that can be used for developing long-acting formulations for hydrophilic molecules along with factors which will affect the choice of the technology. Furthermore, the mechanism of drug release as well as summaries of marketed formulations will be presented. This review also discusses the challenges associated with the manufacturing and scale-up of the long-acting injectables. Graphical abstract

show abstract

Parenteral Controlled and Prolonged Drug Delivery Systems: Therapeutic Needs and Formulation Strategies

Cited by 6 publications

References 193 publications

Oral delivery of protein and peptide drugs: from non-specific formulation approaches to intestinal cell targeting strategies

Oral delivery of protein and peptide drugs: from non-specific formulation approaches to intestinal cell targeting strategies

Injectable Lipid-Based Depot Formulations: Where Do We Stand?

Long-acting parenteral formulations of hydrophilic drugs, proteins, and peptide therapeutics: mechanisms, challenges, and therapeutic benefits with a focus on technologies

Contact Info

Product

Resources

About